稳定冠心病中β受体阻滞剂与钙拮抗剂对死亡率的影响:国际队列研究
多因素校正后,基线β受体阻滞剂使用与全因死亡、心血管死亡及心血管死亡/非致死性心梗复合终点均无显著关联;但既往心梗且在心梗后1年内入组的患者中,β受体阻滞剂使用与较低的全因死亡、心血管死亡及复合终点相关。钙拮抗剂使用与死亡率无显著差异。
要点
- 稳定冠心病总体人群中,β受体阻滞剂使用与5年全因死亡、心血管死亡及复合终点无显著关联。
- 既往心梗且在心梗后1年内入组者,β受体阻滞剂使用与较低全因死亡、心血管死亡及复合终点相关。
- 钙拮抗剂使用与死亡率无显著差异,无论是否有心梗病史。
核心结论
- 在稳定冠心病当代队列中,β受体阻滞剂使用仅在心梗后1年内入组患者中与较低5年死亡率相关。
- 钙拮抗剂使用与死亡率无显著差异,无论是否有心梗病史。
主要发现
- 基线β受体阻滞剂使用与全因死亡无显著关联(HR 0.94,95%CI 0.84-1.06,P=0.30)。
- 基线β受体阻滞剂使用与心血管死亡无显著关联(HR 0.91,95%CI 0.79-1.05,P=0.20)。
- 基线β受体阻滞剂使用与心血管死亡/非致死性心梗复合终点无显著关联(HR 1.03,95%CI 0.91-1.16,P=0.66)。
- 既往心梗且在心梗后1年内入组者,基线β受体阻滞剂使用与较低全因死亡相关(HR 0.68,95%CI 0.50-0.91,P=0.01)。
- 既往心梗且在心梗后1年内入组者,基线β受体阻滞剂使用与较低心血管死亡(HR 0.52,95%CI 0.37-0.73,P=0.0001)及复合终点(HR 0.69,95%CI 0.52-0.93,P=0.01)相关。
临床怎么用
- 稳定冠心病患者中,β受体阻滞剂可能不应普遍用于所有患者以降低死亡率,需结合心梗病史及时间分层决策。
- 心梗后1年内患者使用β受体阻滞剂与较低死亡率相关,支持该时段内应用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The effect of first-line antianginal agents, β-blockers, and calcium antagonists on clinical outcomes in stable coronary artery disease (CAD) remains uncertain. METHODS AND RESULTS: We analysed the use of β-blockers or calcium antagonists (baseline and annually) and outcomes in 22 006 stable CAD patients (enrolled 2009-2010) followed annually to 5 years, in the CLARIFY registry (45 countries). Primary outcome was all-cause death. Secondary outcomes were cardiovascular death and the composite of cardiovascular death/non-fatal myocardial infarction (MI). After multivariable adjustment, baseline β-blocker use was not associated with lower all-cause death [1345 (7.8%) in users vs. 407 (8.4%) in non-users; hazard ratio (HR) 0.94, 95% confidence interval (CI) 0.84-1.06; P = 0.30]; cardiovascular death [861 (5.0%) vs. 262 (5.4%); HR 0.91, 95% CI 0.79-1.05; P = 0.20]; or cardiovascular death/non-fatal MI [1272 (7.4%) vs. 340 (7.0%); HR 1.03, 95% CI 0.91-1.16; P = 0.66]. Sensitivity analyses according to β-blocker use over time and to prescribed dose produced similar results. Among prior MI patients, for those enrolled in the year following MI, baseline β-blocker use was associated with lower all-cause death [205 (7.0%) vs. 59 (10.3%); HR 0.68, 95% CI 0.50-0.91; P = 0.01]; cardiovascular death [132 (4.5%) vs. 49 (8.5%); HR 0.52, 95% CI 0.37-0.73; P = 0.0001]; and cardiovascular death/non-fatal MI [212 (7.2%) vs. 59 (10.3%); HR 0.69, 95% CI 0.52-0.93; P = 0.01]. Calcium antagonists were not associated with any difference in mortality. CONCLUSION: In this contemporary cohort of stable CAD, β-blocker use was associated with lower 5-year mortality only in patients enrolled in the year following MI. Use of calcium antagonists was not associated with superior mortality, regardless of history of MI.
引用
- Sorbets E, Steg PG, Young R, et al. β-blockers, calcium antagonists, and mortality in stable coronary artery disease: an international cohort study. Eur Heart J. 2019. PMID: 30590529. doi:10.1093/eurheartj/ehy811
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。